Adamopoulos P, Athanasopoulou K, Boti M, Dimitroulis G, Daneva G, Tsiakanikas P
RNA Biol. 2023; 20(1):281-295.
PMID: 37272060
PMC: 10243389.
DOI: 10.1080/15476286.2023.2220210.
Castillo P, Aisagbonhi O, Saenz C, ElShamy W
Am J Cancer Res. 2022; 12(1):396-426.
PMID: 35141026
PMC: 8822284.
Krishnan R, Patel P, Hakem R
Cancers (Basel). 2022; 14(1).
PMID: 35008272
PMC: 8749860.
DOI: 10.3390/cancers14010108.
Miklikova S, Trnkova L, Plava J, Bohac M, Kuniakova M, Cihova M
Cancers (Basel). 2021; 13(3).
PMID: 33540843
PMC: 7867315.
DOI: 10.3390/cancers13030575.
Sami E, Paul B, Koziol J, ElShamy W
Cancer Res. 2020; 80(5):1102-1117.
PMID: 31911557
PMC: 7056552.
DOI: 10.1158/0008-5472.CAN-19-2374.
The c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability.
Arason A, Agnarsson B, Johannesdottir G, Johannsson O, Hilmarsdottir B, Reynisdottir I
Genes (Basel). 2019; 10(11).
PMID: 31683985
PMC: 6896150.
DOI: 10.3390/genes10110882.
Targeting mRNA processing as an anticancer strategy.
Desterro J, Bak-Gordon P, Carmo-Fonseca M
Nat Rev Drug Discov. 2019; 19(2):112-129.
PMID: 31554928
DOI: 10.1038/s41573-019-0042-3.
The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells.
Ryan D, Paul B, Koziol J, ElShamy W
Breast Cancer Res. 2019; 21(1):53.
PMID: 31014367
PMC: 6480921.
DOI: 10.1186/s13058-019-1131-2.
BRCA1-No Matter How You Splice It.
Li D, Harlan-Williams L, Kumaraswamy E, Jensen R
Cancer Res. 2019; 79(9):2091-2098.
PMID: 30992324
PMC: 6497576.
DOI: 10.1158/0008-5472.CAN-18-3190.
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation.
Li A, Murphy E, Culhane A, Powell E, Wang H, Bronson R
Proc Natl Acad Sci U S A. 2018; 115(41):E9600-E9609.
PMID: 30254159
PMC: 6187201.
DOI: 10.1073/pnas.1807112115.
Ubiquitin ligase RNF8 suppresses Notch signaling to regulate mammary development and tumorigenesis.
Li L, Guturi K, Gautreau B, Patel P, Saad A, Morii M
J Clin Invest. 2018; 128(10):4525-4542.
PMID: 30222135
PMC: 6160000.
DOI: 10.1172/JCI120401.
Revisiting the roles of VHR/DUSP3 phosphatase in human diseases.
Russo L, Farias J, Ferruzo P, Monteiro L, Forti F
Clinics (Sao Paulo). 2018; 73(suppl 1):e466s.
PMID: 30208163
PMC: 6113852.
DOI: 10.6061/clinics/2018/e466s.
Premature polyadenylation of MAGI3 is associated with diminished N-methyladenosine in its large internal exon.
Ni T, Elman J, Jin D, Gupta P, Kuperwasser C
Sci Rep. 2018; 8(1):1415.
PMID: 29362392
PMC: 5780518.
DOI: 10.1038/s41598-018-19916-8.
A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment.
Ryan D, Sinha A, Bogan D, Davies J, Koziol J, ElShamy W
Oncotarget. 2017; 8(61):103182-103206.
PMID: 29262555
PMC: 5732721.
DOI: 10.18632/oncotarget.20892.
Detecting splicing patterns in genes involved in hereditary breast and ovarian cancer.
Davy G, Rousselin A, Goardon N, Castera L, Harter V, Legros A
Eur J Hum Genet. 2017; 25(10):1147-1154.
PMID: 28905878
PMC: 5602017.
DOI: 10.1038/ejhg.2017.116.
The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D, Meile L, El Bastawisy A, Yousef H, Zekri A, Bahnassy A
BMC Cancer. 2017; 17(1):329.
PMID: 28499366
PMC: 5429567.
DOI: 10.1186/s12885-017-3283-8.
BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
Sinha A, Paul B, Sullivan L, Sims H, El Bastawisy A, Yousef H
Oncotarget. 2017; 8(6):10114-10135.
PMID: 28052035
PMC: 5354646.
DOI: 10.18632/oncotarget.14357.
The role of BRCA1-IRIS in ovarian cancer formation, drug resistance and progression.
ElShamy W
Oncoscience. 2016; 3(5-6):145-6.
PMID: 27489859
PMC: 4965255.
DOI: 10.18632/oncoscience.308.
Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers.
Ananthula S, Sinha A, El Gassim M, Batth S, Marshall Jr G, Gardner L
Oncotarget. 2016; 7(15):20869-89.
PMID: 26989079
PMC: 4991498.
DOI: 10.18632/oncotarget.8029.
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z, Paul B, Craft B, ElShamy W
Breast Cancer Res. 2015; 17:5.
PMID: 25583261
PMC: 4322455.
DOI: 10.1186/s13058-014-0512-9.